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Department of Family and Community Medicine 
Female Sexual 
Dysfunction in Older 
Adults




Review female sexual response 





Define different types of sexual 
dysfunction and risk factors
Review approaches to screening 
for sexual dysfunction in the 
primary care setting
Discuss practical approaches to 
treatment or referral in the 
primary care setting
What I Won’t Be 
Covering...
● Male sexual dysfunction disorder
● Perimenopause or menopausal treatment
● STI Screening Guidelines in Older Adults
● Issues surrounding surgical menopause
● Sexual Dysfunction Treatment Approaches for Trans patients
● Sexual Dysfunction Treatment Approaches for Individuals already 
taking Hormone Therapy for Gender Affirming Care
● Specifics of Physical Therapy Approaches or psychological approaches
● Details of Vaginal CO2 Fractional Laser Treatments
Let’s get started...






“Many physicians approach this as a largely 
biological phenomenon. They are doing a 
disservice to the fact that a woman’s sexual 
experience is an incredibly complex 
phenomenon that is shaped by cultural 
scripting, family-of-origin experience, 
relationship dynamics as well as biological 
factors.”
-Dr. Dennis Sugrue, former president of American 
Association of Sex Educators, Counselors, Therapists
18-44 years 45-64 years 64-85 years
10% 15% 9%
Why should clinicians care? 
Reviewing the epidemiology
43% of American women report experiencing sexual problems
12% consider the problem so bothersome leading to personal distress 





Older adults are 
Asexual Beings
Sexuality comes naturally and 
spontaneously- it doesn’t require 
skills or communication





Medicare Annual Wellness visits 
mandates that weight loss, fall 
prevention, physical activity, cognition, 
vision, hearing, and smoking should be 
addressed, but there are no requirements 




Have any of you had experience 
discussing sexual health or sexual 
concerns with older female patients? 
(brief) Anatomy & 
Physiology Review
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Post-menopausal Changes to Genital Tract
Pelvic Floor








Loss of labial fat pad, 




narrowing of vaginal 
canal, loss of vaginal 
rugae 
Non- Linear Female Sexual 
Response
Sexual Desire = Motivation to Have Sex 
Sexual Arousal = Physiologic Process of arousal 
including vaginal lubrication and genital warmth 















Types of Female Sexual Dysfunction - DSMV
Female Sexual Interest/Arousal Disorder -
DSMV
A. Lack of, significantly reduced, sexual interest/arousal by at least 3 the following: 
a. Absent/reduced interest in sexual activity
b. Absent/reduced sexual/erotic thoughts or fantasies 
c. No/reduced initiation of sexual activity
d. Absent/reduced sexual excitement/pleasure during sexual activity in 75-100% of 
the time
e. Absent/reduced sexual interest/arousal in response to internal or external 
sexual/erotic clues
f. Absent/reduced genital/nongenital sensation during sexual activity 75-100% of 
the time
B. Persisted for minimum duration 6 months
C. Symptoms cause clinically significant distress in the individual 
D. The dysfunction is not better explained by nonsexual mental disorder or consequence 
of severe relationship distress (e.g. IPV), or effects of substance/medication
Female Orgasmic Disorder - DSMV
A. Marked Delay in, marked infrequency of, or absence of 
orgasm, or markedly reduced intensity of orgasmic 
sensation, in almost all or all occasions of sexual activity. 
B. Persisted for minimum duration 6 months




A. The persistent or recurrent presence of one or more of the following symptoms:  
a. Difficulty having intercourse
b. Marked vulvovaginal or pelvic pain during intercourse or penetration 
attempts
c. Marked fear or anxiety about vulvovaginal or pelvic pain anticipating 
during, or resulting from vaginal penetration
d. Marked tensing or tightening of the pelvic floor muscles during attempted 
vaginal penetration
B. Persisted for minimum duration 6 months
C. Symptoms cause clinically significant distress in the individual 
Substance/Medication-Induced Sexual 
Dysfunction - DSMV
A disturbance in sexual function that has temporal relationship with substance 
or medication initiation, dose increase, or substance/medication 
discontinuation and causes clinically significant distress in the individual.*
*Disturbance is not better explained by an independent sexual dysfunction 
disorder. 
Other specified sexual dysfunction and 
other unspecified sexual dysfunction -
“The Leftovers”
Distressing symptoms characteristic of a sexual dysfunction that do no meet 
criteria of one of the defined categories. Major distinction between other 
categories and unspecified sexual dysfunction is whether the clinician 
specifies the reason that the symptoms described do not meet the criteria for 
one of the other classes.
- Pregnancy Related Sexual Dysfunction











Decreased lubrication and pain 
during intercourse
80% of adults age 65 and older have at least 1 
chronic condition, 68% have 2 or more chronic 
conditions. 
Medical Conditions Affecting Sexual Dysfunction
AAFP, 2015
Medication & Substance Review
1.  New medications including OTC medicine and 
vitamins
2. Review recently discontinued meds
3. Review patterns of substance use
AAFP. 2015
So now that we know 
what we’re up 
against...
How do we approach this in the primary care setting> 
Screening for Sexual 
Health Concerns
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How do you 
ask about this?
- “Do you have any concerns about keeping yourself healthy 
and safe?”
- “Many women experience concerns about sex. Are you 
experiencing any issues?
- “Have you been satisfied with the frequency and nature of 
your sexual activities?” 
- “Has anyone ever coerced or forced you to have sex?”
- Take a Sexual history - do an infection risk assessment. 
Journal of American Geriatrics Society, 2018
PLISSIT 
MODEL




















sexual function, life 
stressors
Hint: This may take more than one visit to address. Utilize your behavioral health 
colleagues!
Physical Exam (if indicated)




Role of Estrogen Therapy
(Level A evidence)
- Preferred Treatment for genitourinary syndrome of menopause 
- Vaginal tablets, gels, creams, and rings appear to be equally effective
- Minimal systemic absorption with initial use of vaginal estrogen → absorption 
decreases as epithelium matures
- Low dose vaginal estrogen preferred over low dose systemic estrogen (w/ or w/o 
progestin) for tx of women with only vaginal symptoms
- With vasomotor symptoms, low-dose systemic estrogen is most effective for 
vasomotor AND dysparenunia related to genitourinary syndrome of menopause Image from: mintrx
Data from Cochrane Review 2013, >15 RCTs
Administration
Risks for Breast & Endometrial Cancer
- ACOG Committee Opinion 2016: Women with history of estrogen-dependent 
breast cancer experiencing genitourinary symptoms, vaginal estogen (with or 
without progestins) should be reserved for patients who are unresponsive 
to non-hormonal remedies.  Need a discussion with oncologist. 
- Data does not show increased risk of cancer recurrence among women 
currently undergoing treatment for breast cancer. 
- Systematic Review in peer-reviewed Menopause  2019 (review of 5,593 
abstracts) supports use of low-dose vaginal estrogens for treating vulvar and 
vaginal atrophy in menopausal women without concomitant progestogen. No 
increase endometrial hyperplasia or cancer risk with low-dose unopposed 
vaginal estrogens
Selective Estrogen Receptor Modulator-
SERM
(Level A evidence)
- Ospemifene (Osphena)- agonist effects on estrogen receptors selectively on genital tract 
and antagonist selectively on breast tissue. Has moderate agonist effect on endometrial 
tissue 
- Approved by FDA in 2013 for systemic treatment of genitourinary syndrome of menopause
- 60mg daily for the “shortest possible duration” Clinical trials for this medication lasted mean 
15 months
- Not associated with endometrial cancer of hyperplasia when used continuously for 1 year
- Currently being studied for safe use with estrogen -sensitive cancer
- Can’t be used along with local vaginal estrogen
- Contraindicated in hx of VTE/PE or estrogen-dependent neoplasia
Androgen Therapy - Transdermal Testosterone
(Level B evidence)
- Treatment option for postmenopausal women with sexual interest and 
arousal disorder
- Short-term transdermal testosterone 
- Studied in systematic review of 7 RCTs (n = 3,000), 300 mcgm testosterone 
transdermal patch vs. placebo 
- 3-6 month trial with assessment of testosterone levels at baseline and repeat 
labs after 3-6 weeks of initial use to see levels within normal range for 
reproductive age women.
- Follow up labs q6 months
- Should be discontinued at 6 months if patient doesn’t show a response
- Long term safety and efficacy has not been studied 
- Watching out for hirsutism, acne, virilization (voice deepending, clitoral 
enlargement) 
Androgen Therapy - Systemic DHEA
(Level A evidence)
- Tested but has not shown efficacy in 
postmenopausal women for treatment 
of sexual interest and arousal disorders
- 2015 Cochrane Review did show 
improvement in DHEA versus placebo 
but effect was minimal and not all 
studies focused on females sexual 
dysfunction. 
pharmrx
- Antidepressant-induced female sexual 
dysfunction 
- SSRIs with adverse effect of lowered 
libido
- Mechanism: Norepi-Dopamine Reuptake 
Inhibitor
- Cochrane Review of women and men 
showed addition of moderate dose 
buproprion increased desire, arousal, 
lubrication, and orgasm
- One RCT 2018 of SSRI-induced sexual 
dysfunction, pts with higher dose 150mg 
BID has stastically significant higher 





What about female Viagra? 
Sildenafil Citrate
- Phosphodiesterase Type 5 inhibitor - vasodilating drug
- Evaluated by not approved by the FDA
- Hypothesis: Vasodilation → increased pelvic blood flow, could address female sexual 
interest/arousal disorder or orgasmic disorder
- RCTs have been contradictory 
- One RCT in 2011 showed benefit in women who used SSRIs in medication-induced 
sexual dysfunction (not sexual interest or arousal disorder) 
Flibanserin (Addyi) - not approved in post-menopausal women - $$$







Vaginal Self Dilation - Relief of 
Vaginismus 
Topical Anesthesia with 
Lidocaine
Pelvic Floor Physical Therapy*
Lubricants
Botulinum Toxin A





- Sexual Skills Training 
- Instruction in masturation for 
orgasmic disorders
- Cognitive Behavioral Therapy 
- Mindfulness Based Therapy 
- Focus on stress reduction, shown to 
be effective in sexual interest/arousal 
disorder
- Couples Therapy
- Improving communication with 
partner
- Group-based, couples based CBT
- Identifying and changing 
dysfunctional beliefs




SR is 71 year old F with PMH of HTN, T2DM on metformin, presenting 
for AWV. When asked about her soc hx, she says she has been widowed 
for 4 years but started a new relationship with her neighbor.  You ask about 
any sexual concerns and she says that she had “trouble” having sex with her 
new partner?
● How would you approach this? 
Case 2
LS is a 65 year old F G3P2103 all SVDs with PMH osteopenia, 
coming in because she’s been having pelvic pain with sex. Her 
husband hasn’t had any change in libido and its beginning to 
cause a problem because every time they has sex it’s really 
painful. 
How would you approach this patient?
Summary
- Multifactorial Range of Disorders that require an interdisciplinary approach to Female Sexual 
Dysfunction. Patients can have more than one concurrent disorder!
-Primary Care doctors are well equipped to explore sexual health history and diagnose female sexual 
dysfunction in the clinic 
- A biopsychosocial model of sexual health should be applied when gathering history 
-There are multiple safe and efficacious treatment modalities with pharmacology, physical therapy, 
devices, and psychological approaches to female sexual dysfunction
Resources for More Information on Female 
Sexual Health and Referral 
● Resources for clinicians
○ American Association of Sexuality Educators, Counselors, and Therapist  
www.aamft.org
○ Society for Sex Therapy and Research www.sstarnet.org
○ International Society for the Study of Women’s Sexual Health www.isswsh.org
● Pelvic Physical Therapy - International Pelvic Pain Society www.pelvicpain.org
● Great Books!
○ “Come As You Are” - Emily Nagoski  
○ “Come As You Are Workbook” - https://www.amazon.com/Come-You-Are-
Workbook-practical/dp/1912854554
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